Related Experiment Video
Updated: Aug 19, 2025

A Reporter Assay to Analyze Intronic microRNA Maturation in Mammalian Cells
Published on: June 16, 2022
m6A methyltransferase METTL3 inhibits endometriosis by regulating alternative splicing of MIR17HG
Qian Li1, Li Yang1, Feng Zhang1
1Department of Gynecology, The Third Affiliated Hospital of Zhengzhou University and Henan Province Women and Children's Hospital, Zhengzhou, China.
In Brief:
Inflammation and abnormal immune response are the key processes in the development of endometriosis (EMs), and m6A modification can regulate the inflammatory response. This study reveals that METTL3-mediated N6-methyladenosine (m6A) modification plays an important role in EMs.
Abstract:
m6A modification is largely involved in the development of different diseases. This study intended to investigate the implication of m6A methylation transferase methyltransferase like 3 (METTL3) in EMs. EMs- and m6A-related mRNAs and long non-coding RNAs were identified through bioinformatics analysis. Next, EM mouse models established by endometrial autotransplantation and mouse endometrial stromal cell (mESC) were prepared and treated with oe-METTL3 or sh-MIR17HG for pinpointing the in vitro and in vivo effects of METTL3 on EMs in relation to MIR17HG through the determination of mESC biological processes as well as estradiol (E2) and related lipoprotein levels. We demonstrated that METTL3 and MIR17HG were downregulated in the EMs mouse model. Overexpression of METTL3 suppressed the proliferation, migration, and invasion of mESCs. In addition, METTL3 enhanced the expression of MIR17HG through m6A modification. Moreover, METTL3 could inhibit the E2 level and alter related lipoprotein levels in EMs mice through the upregulation of MIR17HG. The present study highlighted that the m6A methylation transferase METTL3 prevents EMs progression by upregulating MIR17HG expression.
Insights
Methyltransferase like 3 (METTL3) N6-methyladenosine (m6A) modification plays a key role in endometriosis (EMs). METTL3 prevents EMs progression by upregulating MIR17HG expression, impacting cell behavior and hormone levels.
Area of Science:
- Reproductive biology
- Molecular oncology
- Epigenetics
Background:
- Endometriosis (EMs) involves inflammation and abnormal immune responses.
- N6-methyladenosine (m6A) modification regulates inflammatory responses.
- The role of METTL3 in EMs pathogenesis requires further investigation.
Purpose of the Study:
- To investigate the role of methyltransferase like 3 (METTL3) in endometriosis.
- To explore the relationship between METTL3, MIR17HG, and EMs progression.
- To determine the impact of METTL3 on estradiol and lipoprotein levels in EMs.
Main Methods:
- Bioinformatic analysis of EMs- and m6A-related RNAs.
- Establishment of mouse models for endometriosis (EMs) and mouse endometrial stromal cells (mESCs).
- In vitro and in vivo experiments involving METTL3 and MIR17HG manipulation.
Main Results:
- METTL3 and MIR17HG were found to be downregulated in an EMs mouse model.
- Overexpression of METTL3 inhibited mESC proliferation, migration, and invasion.
- METTL3 enhanced MIR17HG expression via m6A modification and suppressed E2 levels in EMs mice.
Conclusions:
- METTL3 plays a protective role in endometriosis.
- METTL3 prevents EMs progression by upregulating MIR17HG expression.
- METTL3 influences key molecular pathways and hormone levels relevant to EMs.
Related Concept Videos
MicroRNAs
RNA Splicing
Master Transcription Regulators
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...

